摘要
目的:探讨替吉奥治疗老年晚期胰腺癌的临床疗效和安全性。方法:2017年1月-2019年1月收治老年晚期胰腺癌患者120例,随机分为两组,各60例。对照组采用吉西他滨治疗;试验组采用替吉奥治疗。比较两组治疗效果。结果:两组治疗6个月、1年生存率比较,差异无统计学意义(P>0.05);两组治疗前后肿瘤标志物指标水平比较,差异无统计学意义(P>0.05);试验组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:替吉奥治疗老年晚期胰腺癌临床疗效较好,安全性较高。
Objective:To investigate the clinical efficacy and safety of tegafur,gimeracil and oteracil potassium in the treatment of advanced pancreatic cancer in the elderly.Methods:From January 2017 to January 2019,120 elderly patients with advanced pancreatic cancer were enrolled,they were randomly divided into two groups of 60 cases in each.The control group was treated with gemcitabine;The experimental group was treated with tegafur,gimeracil and oteracil potassium.The treatment effects of the two groups were compared.Results:The 6-month and 1-year survival rates of the two groups were compared,the differences werenot statistically significant(P>0.05);The tumor marker levels before and after treatment in the two groups were compared,the differences werenot statistically significant(P>0.05);The incidence of adverse reactions in the experimental group was lower than in the control group,the difference was statistically significant(P<0.05).Conclusion:Tegafur,gimeracil and oteracil potassium is effective and safe in the treatment of advanced pancreatic cancer in the elderly.
作者
李宪友
Li Xianyou(The People's Hospital of Kaijiang County,Sichuan Dazhou 636250)
出处
《中国社区医师》
2020年第5期58-58,60,共2页
Chinese Community Doctors
关键词
替吉奥
老年胰腺癌
吉西他滨
Tegafur
gimeracil and oteracil potassium
Pancreatic cancer in the elderly
Gemcitabine
